Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Restart Life Sciences Cp (OP:NMLSF)

0.0713 UNCHANGED
Streaming Delayed Price Updated: 3:20 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Restart Life Sciences Cp

News headline image
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
News headline image
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism ↗
The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started < 
Via Benzinga
News headline image
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
News headline image
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder ↗
Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a... 
Via Benzinga
News headline image
Nova Mentis Is Looking To Treat Autism With Psilocybin ↗
Nova Mentis Life Science Corp. (OTCQB: NMLSF) and the private college Toronto Institute of Pharmaceutical Technology have signed a ... 
Via Benzinga
News headline image
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval ↗
The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a... 
Via Benzinga
News headline image
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project ↗
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... 
Via Benzinga
News headline image
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial ↗
Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB: NMLSF) and Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Sciences Inc. 
Via Benzinga
News headline image
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial ↗
Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science... 
Via Benzinga
News headline image
Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin ↗
Amended Autopsy Confirms Elijah McClain Died From Ketamine Injected By Paramedics Called By Cops 
Via Benzinga
News headline image
Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn ↗
Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry,... 
Via Benzinga
News headline image
New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details ↗
Canadian-based psychedelics company Nova Mentis Life Science Corp. 
Via Benzinga
News headline image
More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases ↗
The Canadian biotech company Nova Mentis Life Science Corp. (OTCQB: NMLSF) is filing new provisional patent applications to the U.S. 
Via Benzinga
News headline image
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies ↗
The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs. 
Via Benzinga
News headline image
Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened ↗
Nova Mentis Life Science Corp. (OTCQB: NMLSF), also known as NOVA, a biotech company developing psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, recently... 
Via Benzinga
News headline image
Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study ↗
Psilocybin received yet another confirmation of its beneficial effects in the treatment of major depressive disorder, this time, in the long term. ... 
Via Benzinga
News headline image
This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism ↗
Nova Mentis Life Science Corp (OTCQB: NMLSF) is a biotechnology company focused on psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. The... 
Via Benzinga
News headline image
Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market ↗
Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis ↗
The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application  to Health Canada   
Via Benzinga
News headline image
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval ↗
Detroit Decriminalizes Psychedelics 
Via Benzinga
News headline image
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent ↗
The Week In Psychedelics 
Via Benzinga
News headline image
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗
The Week In Psychedelics 
Via Benzinga
News headline image
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.